Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tsoukas

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|February 23, 2026
Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in CanadaEthan S McNally, Pedro Marques, Elite Possik, et al.
Annals of Vascular Surgery|March 1, 1991
Angioscopy of arm vein infrainguinal bypass graftsP A Stonebridge, A Miller, A Tsoukas, et al.
Canadian Journal of Diabetes|May 29, 2019
CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical PracticeVincent Woo, Alan Bell, Maureen Clement, et al.
Surgery|March 1, 1991
Continued experience with intraoperative angioscopy for monitoring infrainguinal bypass graftingA Miller, P A Stonebridge, S J Jepsen, et al.
Archives of Surgery (Chicago, Ill. : 1960)|June 1, 1990
New angioscopic findings in graft failure after infrainguinal bypassA Miller, S J Jepsen, P A Stonebridge, et al.
Obesity (Silver Spring, Md.)|July 24, 2024
Age of obesity onset affects subcutaneous adipose tissue cellularity differently in the abdominal and femoral regionJessica Murphy, Abdulrahman Dera, José A Morais, et al.
Diabetes, Obesity & Metabolism|November 6, 2018
CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practiceVincent Woo, Alan Bell, Maureen Clement, et al.
Diabetes, Obesity & Metabolism|March 21, 2023
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCEMichael A Tsoukas, Vincent Woo, Sheldon W Tobe, et al.
Diabetes Care|November 20, 2025
Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 DiabetesTimothy E Graham, Dan Raghinaru, Samina Afreen, et al.
Diabetes, Obesity & Metabolism|September 20, 2024
Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trialAmir Razaghizad, Jiayi Ni, Pedro Marques, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|February 23, 2026
Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in CanadaEthan S McNally, Pedro Marques, Elite Possik, et al.
Annals of Vascular Surgery|March 1, 1991
Angioscopy of arm vein infrainguinal bypass graftsP A Stonebridge, A Miller, A Tsoukas, et al.
Canadian Journal of Diabetes|May 29, 2019
CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical PracticeVincent Woo, Alan Bell, Maureen Clement, et al.
Surgery|March 1, 1991
Continued experience with intraoperative angioscopy for monitoring infrainguinal bypass graftingA Miller, P A Stonebridge, S J Jepsen, et al.
Archives of Surgery (Chicago, Ill. : 1960)|June 1, 1990
New angioscopic findings in graft failure after infrainguinal bypassA Miller, S J Jepsen, P A Stonebridge, et al.
Obesity (Silver Spring, Md.)|July 24, 2024
Age of obesity onset affects subcutaneous adipose tissue cellularity differently in the abdominal and femoral regionJessica Murphy, Abdulrahman Dera, José A Morais, et al.
Diabetes, Obesity & Metabolism|November 6, 2018
CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practiceVincent Woo, Alan Bell, Maureen Clement, et al.
Diabetes, Obesity & Metabolism|March 21, 2023
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCEMichael A Tsoukas, Vincent Woo, Sheldon W Tobe, et al.
Diabetes Care|November 20, 2025
Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 DiabetesTimothy E Graham, Dan Raghinaru, Samina Afreen, et al.
Diabetes, Obesity & Metabolism|September 20, 2024
Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trialAmir Razaghizad, Jiayi Ni, Pedro Marques, et al.
Pageof 9